Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor.

Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK.

Genes Dev. 2002 Jun 15;16(12):1466-71.

2.

Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor.

Li Z, Wang D, Na X, Schoen SR, Messing EM, Wu G.

Biochem Biophys Res Commun. 2002 Jun 14;294(3):700-9.

PMID:
12056827
3.

Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch.

Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML.

Science. 2002 Feb 1;295(5556):858-61.

4.

Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein.

Li Z, Na X, Wang D, Schoen SR, Messing EM, Wu G.

J Biol Chem. 2002 Feb 15;277(7):4656-62. Epub 2001 Dec 5.

5.
6.

A conserved family of prolyl-4-hydroxylases that modify HIF.

Bruick RK, McKnight SL.

Science. 2001 Nov 9;294(5545):1337-40. Epub 2001 Oct 11.

7.

C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation.

Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ.

Cell. 2001 Oct 5;107(1):43-54.

8.

Selection of mutant CHO cells with constitutive activation of the HIF system and inactivation of the von Hippel-Lindau tumor suppressor.

Vaux EC, Wood SM, Cockman ME, Nicholls LG, Yeates KM, Pugh CW, Maxwell PH, Ratcliffe PJ.

J Biol Chem. 2001 Nov 23;276(47):44323-30. Epub 2001 Sep 12.

9.

HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.

Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG Jr.

Science. 2001 Apr 20;292(5516):464-8. Epub 2001 Apr 5.

10.

Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ.

Science. 2001 Apr 20;292(5516):468-72. Epub 2001 Apr 5.

12.

Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor.

Haase VH, Glickman JN, Socolovsky M, Jaenisch R.

Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1583-8.

13.
14.

Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex.

Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW.

Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10430-5.

15.

HIF-1 and human disease: one highly involved factor.

Semenza GL.

Genes Dev. 2000 Aug 15;14(16):1983-91. Review. No abstract available.

16.
17.

VHL takes HIF's breath away.

Krek W.

Nat Cell Biol. 2000 Jul;2(7):E121-3.

PMID:
10878820
18.

Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein.

Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG.

Nat Cell Biol. 2000 Jul;2(7):423-7.

PMID:
10878807
19.

Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.

Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH.

J Biol Chem. 2000 Aug 18;275(33):25733-41.

20.
Items per page

Supplemental Content

Write to the Help Desk